Definium Therapeutics
DFTX
35.09
-0.53
-1.49%
Definium Therapeutics
US · DFTX
#2132 by market cap
Listed 1970
35.09
-0.53
-1.49%
Live - 5344 symbols - heartbeat 263s ago
· 2026-10-08 06:47
Pre-market
34.76
-0.94%
After-hours
35.07
-0.06%
Overnight
35.86
+2.19%
- Market cap
- 4.71B
- P/E (TTM)i
- -10.23
- P/Bi
- 5.13
- EPSi
- -2.06
- Div yieldi
- 0.00%
- 52W posi
- 63%
Reader sentiment
Are you bullish or bearish on DFTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- The number of reporting institutions increased by 2 in the most recent period (2026/Q3).
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 87.51% -0.01pp
- Institutions
- 414 +2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund57.29%
Hedge Fund21.23%
VC/PE Fund5.65%
Public Company1.65%
Individual/Insider1.49%
Insurance Company0.56%
Private Company0.42%
Family Office/Trust0.35%
Government Pension Fund0.30%
Other11.06%
Top holders as of 2026-06-30
BlackRock
8.36% · 11.23M sh
Capital Research
6.20% · 8.33M sh
Avoro Capital Advisors LLC
5.35% · 7.19M sh
Driehaus Capital Management LLC
5.09% · 6.85M sh
Janus Henderson Group plc
4.18% · 5.62M sh
FMR
3.54% · 4.75M sh
T. Rowe Price Group, Inc.
3.46% · 4.65M sh
Geode Capital Management, LLC
2.71% · 3.64M sh
State Street Global Advisors
2.28% · 3.07M sh
Octagon Capital Advisors LP
2.20% · 2.95M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 36 buys · 14 sells
| Name | Role | Stake |
|---|---|---|
| Daniel Karlin | Chief Medical Officer | 0.43% |
| Robert Barrow | Chief Executive Officer | 0.33% |
| Matthew Wiley | Chief Commercial Officer | 0.27% |
| Brandi Roberts | Chief Financial Officer | 0.20% |
| Mark Sullivan | Chief Legal Officer | 0.19% |
| Schond Greenway | Chief Financial Officer | 0.02% |
| Roger Crystal | Independent Director | 0.01% |
| Suzanne Bruhn | Independent Director | 0.01% |
| Carol Vallone | Independent Chairperson | 0.01% |
| Andreas Krebs | Independent Vice Chairperson | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-24 | Mark Sullivan | Chief Legal Officer | Automatic Disposition | -14,051 | $36.57 |
| 2026-09-24 | Brandi Roberts | Chief Financial Officer | Automatic Disposition | -3,377 | $36.57 |
| 2026-09-24 | Matthew Wiley | Chief Commercial Officer | Automatic Disposition | -3,097 | $36.57 |
| 2026-09-24 | Robert Barrow | Chief Executive Officer | Automatic Disposition | -31,550 | $36.57 |
| 2026-09-24 | Daniel Karlin | Chief Medical Officer | Automatic Disposition | -10,853 | $36.57 |
| 2026-09-17 | Carol Vallone | Independent Chairperson | Derivative Exercise and Retained | +1,086 | $35.52 |
| 2026-09-17 | Andreas Krebs | Independent Vice Chairperson | Derivative Exercise and Retained | +1,629 | $35.52 |
| 2026-09-13 | Mark Sullivan | Chief Legal Officer | Other Acquisition | +125,000 | -- |
| 2026-09-13 | Brandi Roberts | Chief Financial Officer | Other Acquisition | +125,000 | -- |
| 2026-09-13 | Matthew Wiley | Chief Commercial Officer | Other Acquisition | +125,000 | -- |
| 2026-09-13 | Robert Barrow | Chief Executive Officer | Other Acquisition | +750,000 | -- |
| 2026-09-13 | Daniel Karlin | Chief Medical Officer | Other Acquisition | +200,000 | -- |
| 2026-09-02 | Robert Barrow | Chief Executive Officer | Automatic Disposition | -19,023 | $37.94 |
| 2026-09-01 | Robert Barrow | Chief Executive Officer | Other Acquisition | +40,000 | -- |
| 2026-08-11 | Mark Sullivan | Chief Legal Officer | Other Acquisition | +62,500 | -- |
| 2026-08-11 | Brandi Roberts | Chief Financial Officer | Other Acquisition | +62,500 | -- |
| 2026-08-11 | Matthew Wiley | Chief Commercial Officer | Other Acquisition | +62,500 | -- |
| 2026-08-11 | Robert Barrow | Chief Executive Officer | Other Acquisition | +375,000 | -- |
| 2026-08-11 | Daniel Karlin | Chief Medical Officer | Other Acquisition | +100,000 | -- |
| 2026-06-24 | Mark Sullivan | Chief Legal Officer | Automatic Disposition | -13,008 | $45.03 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 06:47:10 · For reference only, not investment advice and not tailored to your situation.